Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 395

1.

An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation.

Xu FH, Xiong D, Xu YF, Cao SM, Xue WQ, Qin HD, Liu WS, Cao JY, Zhang Y, Feng QS, Chen LZ, Li MZ, Liu ZW, Liu Q, Hong MH, Shugart YY, Zeng YX, Zeng MS, Jia WH.

J Natl Cancer Inst. 2012 Sep 19;104(18):1396-410. Epub 2012 Sep 12.

2.

Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan.

Hsu WL, Chen JY, Chien YC, Liu MY, You SL, Hsu MM, Yang CS, Chen CJ.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1218-26. doi: 10.1158/1055-9965.EPI-08-1175. Epub 2009 Mar 31.

3.

Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.

Gu AD, Lu LX, Xie YB, Chen LZ, Feng QS, Kang T, Jia WH, Zeng YX.

J Transl Med. 2009 Aug 23;7:73. doi: 10.1186/1479-5876-7-73.

4.

[Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].

Yi B, Gu YL, Zong YS, Cheng WM, Ji MF.

Ai Zheng. 2009 Aug;28(8):822-6. Chinese.

PMID:
19664327
5.

Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.

Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.

Cancer. 2004 Mar 15;100(6):1162-70.

6.

The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types.

Abdulamir AS, Hafidh RR, Abdulmuhaimen N, Abubakar F, Abbas KA.

BMC Public Health. 2008 Dec 5;8:400. doi: 10.1186/1471-2458-8-400.

7.
8.

Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.

Ji MF, Huang QH, Yu X, Liu Z, Li X, Zhang LF, Wang P, Xie SH, Rao HL, Fang F, Guo X, Liu Q, Hong MH, Ye W, Zeng YX, Cao SM.

Cancer. 2014 May 1;120(9):1353-60. doi: 10.1002/cncr.28564. Epub 2014 Jan 29.

9.

Inhibition of nasopharyngeal carcinoma growth by RTA-expressing baculovirus vectors containing oriP.

Wang L, Shan L, Lo KW, Yin J, Zhang Y, Sun R, Zhong J.

J Gene Med. 2008 Oct;10(10):1124-33. doi: 10.1002/jgm.1237.

PMID:
18642396
10.

Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China.

Zheng X, Yan L, Nilsson B, Eklund G, Drettner B.

Acta Oncol. 1994;33(8):867-72.

PMID:
7818917
11.

Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum.

Cheng WM, Chan KH, Chen HL, Luo RX, Ng SP, Luk W, Zheng BJ, Ji MF, Liang JS, Sham JS, Wang DK, Zong YS, Ng MH.

Int J Cancer. 2002 Feb 1;97(4):489-92. Erratum in: Int J Cancer 2002 Apr 20;98(6):957.

12.

Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia.

Hutajulu SH, Ng N, Jati BR, Fachiroh J, Herdini C, Hariwiyanto B, Haryana SM, Middeldorp JM.

J Med Virol. 2012 May;84(5):768-76. doi: 10.1002/jmv.23263.

PMID:
22431025
13.

[Detection of serum Epstein-Barr virus antibody level by ELISA in normal populations and nasopharyngeal carcinoma patients in Zhongshan City of China].

Cheng MT, Cheng WM, Ji MF, Liang JS.

Di Yi Jun Yi Da Xue Xue Bao. 2002 Sep;22(9):817-8, 822. Chinese.

PMID:
12297441
14.

Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.

Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM.

Clin Vaccine Immunol. 2009 May;16(5):706-11. doi: 10.1128/CVI.00425-08. Epub 2009 Mar 25.

15.

Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.

Wu CC, Chuang HY, Lin CY, Chen YJ, Tsai WH, Fang CY, Huang SY, Chuang FY, Lin SF, Chang Y, Chen JY.

Mol Carcinog. 2013 Dec;52(12):946-58. doi: 10.1002/mc.21926. Epub 2012 May 29.

PMID:
22641235
16.

Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.

Baizig NM, Morand P, Seigneurin JM, Boussen H, Fourati A, Gritli S, Oueslati Z, Touati S, Gamoudi A, Ben Abdallah M, El May M, El May A.

Eur Arch Otorhinolaryngol. 2012 Mar;269(3):1005-11. doi: 10.1007/s00405-011-1717-5. Epub 2011 Jul 30.

PMID:
21805179
17.

Nuclear factor-Y and Epstein Barr virus in nasopharyngeal cancer.

Chia MC, Leung A, Krushel T, Alajez NM, Lo KW, Busson P, Klamut HJ, Bastianutto C, Liu FF.

Clin Cancer Res. 2008 Feb 15;14(4):984-94. doi: 10.1158/1078-0432.CCR-07-0828.

18.

Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency.

Chen CJ, Liang KY, Chang YS, Wang YF, Hsieh T, Hsu MM, Chen JY, Liu MY.

Anticancer Res. 1990 Mar-Apr;10(2B):547-53.

PMID:
2161639
19.

[Evaluation of detection of Epstein-Barr virus Rta/IgG in nasopharyngeal carcinoma].

Zheng YM, Cain YL, Cheng JR, Li J, Mo YK, Gao JQ, Dong ZR, Zhong QY.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2009 Aug;23(4):285-7. Chinese.

PMID:
20108775
20.

Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects.

Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, Middeldorp JM.

J Infect Dis. 2004 Jul 1;190(1):53-62. Epub 2004 May 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk